MVI Finance
5
10M
1
0.80
- Areas of investment
Summary
The fund is generally included in less than 2 deals every year. The usual things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2004.
Besides, a startup needs to be aged 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Life Science, Genetics. Among the various public portfolio startups of the fund, we may underline Genizon BioSciences
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the MVI Finance, startups are often financed by HBM Healthcare Investments AG, Biotech Turnaround Fund (BTF), BioFund Management. The meaningful sponsors for the fund in investment in the same round are HBM Healthcare Investments AG, Carnegie Asset Management, Biotech Turnaround Fund (BTF). In the next rounds fund is usually obtained by HBM Healthcare Investments AG, Biotech Turnaround Fund (BTF), BioFund Management.
Investments analytics
Analytics
- Total investments
- 5
- Lead investments
- 0
- Follow on index
- 0.80
- Investments by industry
- Genetics (5)
- Biotechnology (5)
- Medical Device (5)
- Life Science (5)
- Investments by region
-
- Canada (5)
- Peak activity year
- 2004
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 22
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Genizon BioSciences | 13 Dec 2004 | Biotechnology, Genetics, Medical Device, Life Science | Early Stage Venture | 8M | Quebec, Montreal, Canada |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.